Junlin Ho Sells 4,695 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 4,695 shares of Scholar Rock stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $8.98, for a total value of $42,161.10. Following the completion of the sale, the general counsel now directly owns 204,076 shares in the company, valued at $1,832,602.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $8.49 on Thursday. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.58 and a quick ratio of 6.58. Scholar Rock Holding Co. has a 52-week low of $5.93 and a 52-week high of $21.17. The business has a 50-day moving average price of $12.24 and a 200 day moving average price of $14.85.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). During the same quarter in the previous year, the business earned ($0.46) earnings per share. Equities analysts predict that Scholar Rock Holding Co. will post -2.4 EPS for the current year.

Institutional Trading of Scholar Rock

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Walleye Trading LLC purchased a new stake in Scholar Rock during the 1st quarter valued at approximately $178,000. Jane Street Group LLC increased its stake in Scholar Rock by 95.5% in the 1st quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock valued at $4,339,000 after purchasing an additional 119,363 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Scholar Rock in the 1st quarter valued at approximately $4,900,000. Bayesian Capital Management LP purchased a new position in Scholar Rock in the 1st quarter valued at approximately $258,000. Finally, Redmile Group LLC increased its stake in Scholar Rock by 0.3% in the 1st quarter. Redmile Group LLC now owns 6,419,610 shares of the company’s stock valued at $114,012,000 after purchasing an additional 17,105 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on SRRK. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 26th. Raymond James started coverage on Scholar Rock in a research note on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a research report on Tuesday, May 7th. BMO Capital Markets lifted their target price on Scholar Rock from $29.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, June 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Scholar Rock in a report on Tuesday, June 4th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.